IHS Chemical Week

Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients

Pharma/fine chemicals roundup—23 April

12:16 PM MDT | April 23, 2013 | Deepti Ramesh

Hikma to retain injectables business Hikma Pharmaceuticals (London) says it has concluded a review of the strategic options for its global Injectables business and decided that this business should remain part of the Hikma group. Hikma's operations are conducted through three pharmaceutical businesses—branded, injectables, and generics, based mainly in the Mideast and North Africa regions, the United States, and Europe. Hikma recorded sales of about $1.1 billion in 2012. “After a thorough review of strategic options for the injectables business, we...

This information is only available to Chemical Week subscribers.

Username:
Password:

Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

Not an IHS Chemical Week
24/7 member yet?

Here's why you should be:

  • Searchable online archive access of the last 2 years of Chemical Week.
  • Print or digital magazine subscription
  • Price and market change alerts
  • Economic data and statistics
  • Buyers' Guides
  • Webcasts | whitepapers

 

 

 













 
contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2014 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa